ALGSAligos Therapeutics Inc
About Aligos Therapeutics Inc
Aligos Therapeutics (NASDAQ:ALGS) focuses on developing novel therapeutics that address unmet medical needs in liver diseases, including chronic hepatitis B, NASH (nonalcoholic steatohepatitis), and liver and respiratory diseases caused by coronaviruses. The company dedicates itself to groundbreaking research and the advancement of treatments that can provide significant benefits over existing therapies. Through rigorous scientific investigation and clinical trials, Aligos aims to revolutionize the management and care of patients suffering from these serious conditions. Emphasizing innovation and effectiveness, the company's projects are designed to navigate the complexities of liver diseases and to halt or reverse the progression of illnesses, with the ultimate objective of enhancing the quality of life for patients worldwide.
What is ALGS known for?
Snapshot
Public US
Ownership
2018
Year founded
66
Employees
South San Francisco, United States
Head office
1 of 2
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
South San Francisco, US
Products and/or services of Aligos Therapeutics Inc
- Development of antiviral therapeutics for chronic hepatitis B (CHB) designed to provide a functional cure.
- Research on oligonucleotide platform targeting various RNA-based therapies for liver diseases.
- Innovations in small molecule therapeutics aimed at modulating liver disease pathways.
- Advancement of antiviral drugs for treating respiratory syncytial virus (RSV), offering a new approach to manage infections.
- Collaboration on developing siRNA (small interfering RNA) therapeutics for addressing unmet needs in viral diseases.
- Progression of non-alcoholic steatohepatitis (NASH) treatments, focusing on reducing liver fat and inflammation.
Aligos Therapeutics Inc executive team
- Dr. Lawrence M. Blatt MBA, Ph.D.CEO, President & Chairman of the Board
- Ms. Lesley Ann Calhoun CPAExecutive VP, CFO & COO
- Dr. Julian A. Symons DPHILExecutive VP & Chief Scientific Officer
- Ms. Laura KavanaughVP & Head of Legal
- Ms. Kristina Engeseth M.B.A.Senior VP and Head of People & Culture
- Dr. Sushmita M. Chanda DABT, Ph.D.Executive Vice President & Chief Development Officer
- Dr. David B. Smith Ph.D.Executive VP & Head of Chemical Operations
- Dr. Tse-I Lin Ph.D.Senior VP of Early Compound Development & Belgian Site Head
- Dr. Kieron Wesson Ph.D.Vice President & Head of Chemistry Manufacturing Controls
- Dr. Ramon Polo M.B.A., Ph.D., Pharm.D.Senior VP & Head of Global Regulatory Affairs